EU RevenuesThere has been a recent uptick in EU Vazkepa revenues driven by broader market access and steady growth in adoption across European countries.
Financial StabilityAmarin currently has a cash position of $281.8M with no debt, which supports continued efforts of the company to maintain prudent cash deployment while pursuing growth for Vazkepa ex-US.
NASDAQ ComplianceAmarin’s 1-for-20 ADS ratio change has led to regained NASDAQ compliance, which lowered the company’s existing share count.
Patent ProtectionEU patent protection extends exclusivity to 2039, which could enhance the stock's value.